trending Market Intelligence /marketintelligence/en/news-insights/trending/A6YC1x8SwxcDd0etpf53pg2 content esgSubNav
In This List

VistaGen closes $15M common stock, warrants offering

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


VistaGen closes $15M common stock, warrants offering

VistaGen Therapeutics Inc. raised about $15 million in gross proceeds from its public offering of 10 million common shares and warrants to buy up to 10 million shares at $1.50 apiece.

Each common share was sold together with a warrant to buy 1 common share. The warrants are exercisable for $1.50 apiece within a five-year term.

VistaGen plans to use the net proceeds for research and development as well as for ordinary course working capital needs and other general corporate purposes.

Oppenheimer & Co. Inc. acted as a sole book-running manager, while Chardan acted as lead manager for the offering.